Cytori Therapeutics Inc (NASDAQ:CYTX) shot up 16.1% during mid-day trading on Wednesday . The company traded as high as $0.37 and last traded at $0.36. 1,820,975 shares changed hands during mid-day trading, a decline of 23% from the average session volume of 2,367,844 shares. The stock had previously closed at $0.31.
A number of research firms recently issued reports on CYTX. B. Riley restated a “hold” rating on shares of Cytori Therapeutics in a report on Tuesday, November 7th. Zacks Investment Research downgraded shares of Cytori Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 9th. Maxim Group set a $5.00 price objective on shares of Cytori Therapeutics and gave the stock a “buy” rating in a research note on Monday, November 13th. Finally, ValuEngine upgraded shares of Cytori Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd.
The firm has a market cap of $12.60, a P/E ratio of -0.40 and a beta of 3.56.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Perkins Capital Management Inc. grew its stake in Cytori Therapeutics by 134.0% during the fourth quarter. Perkins Capital Management Inc. now owns 2,136,041 shares of the biotechnology company’s stock worth $644,000 after buying an additional 1,223,046 shares during the period. Sabby Management LLC lifted its position in shares of Cytori Therapeutics by 28.0% during the second quarter. Sabby Management LLC now owns 1,626,807 shares of the biotechnology company’s stock worth $1,789,000 after purchasing an additional 355,504 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Cytori Therapeutics by 81.9% during the second quarter. Vanguard Group Inc. now owns 612,304 shares of the biotechnology company’s stock worth $674,000 after purchasing an additional 275,653 shares in the last quarter. Institutional investors own 10.82% of the company’s stock.
About Cytori Therapeutics
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.